Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-3: KTE-X19 in Adult r/r ALL
NCT02614066Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Mar 2016
- Primary completion
- Jul 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 5
01
Overview
A Phase 2 trial of brexucabtagene autoleucel in acute lymphoblastic leukemia (ALL), sponsored by Kite Pharma. Started Mar 2016; status: completed.
02
Drugs
brexucabtagene autoleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02614066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614066.